Introduction
============

The cell nucleolus is a dynamic, non-membrane-bound subnuclear structure, which has a classically well-established role in ribosome biogenesis, including the synthesis and processing of the ribosomal RNA (rRNA) precursor molecules (pre-rRNAs) and the assembly of pre-rRNAs with particular ribosomal and nonribosomal proteins to form preribosomal particles ([@b1-ol-0-0-4450],[@b2-ol-0-0-4450]). Mammalian nuclei typically contain one nucleolus, whereas tumor cells tend to contain several nucleoli ([@b3-ol-0-0-4450]). The typical tripartite organization of the nucleolus in mammals, which accounts for ribosomal gene transcription and pre-rRNA processing efficiency, is composed of three distinct components: The fibrillar center (FC), the dense fibrillar component (DFC) and the granular component (GC) ([@b4-ol-0-0-4450]--[@b7-ol-0-0-4450]). The early accumulation and processing of rRNA takes place in the DFC, whereas late rRNA processing and building of the ribosomal components occurs in the GC ([@b2-ol-0-0-4450]). As well as small nucleolar RNAs, a number of proteins, including fibrillarin and nucleolar phosphoprotein B23 (B23), are located in the nucleolus ([@b6-ol-0-0-4450]). With regard to the unique nulceolar localization in the cells at interphase, fibrillarin and B23 are also widely used as markers for the DFC and GC, respectively ([@b8-ol-0-0-4450]).

Previous studies have indicated that the nucleolus is plurifunctional ([@b9-ol-0-0-4450],[@b10-ol-0-0-4450]). In addition to the typically recognized function of ribosome biosynthesis, the nucleolus supports the production of additional gene expression components, including transfer RNA and translational apparatus, the signal recognition particle, ribonucleoprotein enzyme involved in maintenance of telomerase integrity and U6 RNA, a catalytic RNA of the spliceosome ([@b9-ol-0-0-4450]).

Small G protein ras homolog family member A (RhoA), with a molecular weight of 21 kDa, is the most extensively studied member of the Rho guanosine triphosphate (GTP)ase family and is part of the Ras super family of small G proteins ([@b11-ol-0-0-4450]). RhoA has been reported to regulate numerous biological activities, including gene transcription ([@b12-ol-0-0-4450]) and tumor progression ([@b13-ol-0-0-4450]). Recent research on the intracellular localization of RhoA has shown that it is located not only in the cytosol and cell membrane, but also in the cell nucleus ([@b14-ol-0-0-4450]--[@b16-ol-0-0-4450]). Notably, previous studies have demonstrated that the nuclear localization of RhoA with predominant concentration in the cell nucleolus is a common feature in human cancer tissues and cell lines ([@b17-ol-0-0-4450],[@b18-ol-0-0-4450]). Although our previous study has demonstrated that the nuclear translocation of RhoA is via active transport, a process involving importin α in a nuclear factor-κB1-dependent manner, the mechanism, biological function and pathological meaning of the nucleolar residency of RhoA remain to be elucidated ([@b18-ol-0-0-4450]).

The antitumor antibiotic actinomycin D is a polypeptide antibiotic that is widely used as inhibitor of RNA synthesis. Actinomycin D is able to bind to duplex DNA and inhibit the progression of DNA-dependent RNA polymerase ([@b19-ol-0-0-4450],[@b20-ol-0-0-4450]). Studies on the subcellular distribution of B23 have demonstrated consistently that it is sensitive to actinomycin D treatment and translocates from the cell nucleoli to alternative regions of the nucleus ([@b21-ol-0-0-4450]--[@b24-ol-0-0-4450]). By contrast, the results of studies regarding the subcellular distribution of fibrillarin with actinomycin D treatment are diverse ([@b25-ol-0-0-4450]--[@b27-ol-0-0-4450]). A previous study demonstrated that nucleolar fibrillarin also redistributed to nucleoplasmic entities in response to actinomycin D treatment in HEp-2 cells ([@b28-ol-0-0-4450]).

By utilizing an RNA synthesis inhibitor, the present study aimed to investigate the association between RNA synthesis and the nucleolar concentration of RhoA in human HEp-2 cells, as well as the potential molecular mechanisms underlying the nucleolar residency of RhoA.

Materials and methods
=====================

### Cell lines and cell culture

Human carcinoma HEp-2 cells, which were originally derived from an epidermoid carcinoma of the larynx, purchased from the American Type Culture Collection (Manassas, VA, USA) were maintained in complete RPMI-1640 that contained 10% fetal bovine serum (FBS) and was supplemented with L-glutamine (2 mmol/l), salt pyruvate (1 mmol/l), 1% non-essential amino acids and streptomycin (10 mg/l), at 37°C in a humidified atmosphere of 5% CO~2~. The cell culture medium was replaced every two days and the cells were maintained at subconfluence.

### Reagents

RPMI-1640 culture medium and FBS were obtained from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). L-glutamine, salt pyruvate, non-essential amino acids, streptomycin, phosphate-buffered saline (PBS) and nuclear fluorochrome Hoechst 33342 were obtained from Sigma-Aldrich (St. Louis, MO, USA). Primary antibodies against RhoA (monoclonal mouse; \#sc-418; dilution, 1:200) and fibrillarin (mouse monoclonal; \#sc-166000; dilution, 1:100) were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA), whereas monoclonal mouse antibody against B23 (\#B0556; dilution, 1:100) was purchased from Sigma-Aldrich. Actinomycin D was additionally obtained from Sigma-Aldrich. Mouse monoclonal antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH; \#KC-5G4; dilution, 1:5,000) was obtained from KangCheng Bio-tech Inc. (Shanghai, China). Goat anti-mouse immunoglobulin (Ig)G fluorescein isothiocyanate-conjugated (FITC; \#115-097-003; dilution, 1:1,000) and goat anti-mouse IgG horseradish peroxidase (HRP)-conjugated (\#115-035-209; dilution, 1:5,000) secondary antibodies were obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). Enhanced chemiluminescence (ECL) reagents were purchased from GE Healthcare Life Sciences (Chalfont, UK).

### Actinomycin D treatment

A stock solution of actinomycin D (2.5 g/l) was prepared in ethanol (Changzhou Yabang Chemical Co.,Ltd., Changzhou, China). It was diluted at least 2,500-fold and freshly prepared prior to addition to the cells. For the reversibility assay, HEp-2 cells grown on cover slips in a 6-well plate (Genetimes Biological Mall, Shanghai, China) were treated with actinomycin D. Following treatment, cover slips were washed 3 times (1 min each wash) in prewarmed PBS, followed by 1 brief wash with prewarmed fresh cell culture medium without actinomycin D. Subsequent to treatment with actinomycin D at the concentrations of 0.05 mg/l (for 4 h) and 1 mg/l (for 1 h), cells were cultivated in fresh culture medium without actinomycin D for an additional incubation of 24 or 27 h, which was dependent on the re-accumulation of RhoA in the cell nucleolus.

### Immunofluorescence microscopy

HEp-2 cells grown on cover slips were fixed with freshly prepared paraformaldehyde (Nantong Jiangtian Chemical Co., Ltd., Nangtong, China) (40 g/l in PBS) for 30 min. Subsequent to being penetrated with 30 ml/l Triton X-100 (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) for 8 min and blocked with 30 g/l bovine serum albumin (Genetimes Biological Mall) for 1 h, the cells were incubated with the primary antibodies against RhoA, fibrillarin or B23 at 4°C overnight, followed by another incubation with the species-specific anti-IgG FITC-conjugated secondary antibody for 1 h at room temperature. Cells were washed three times with PBS (10 min each wash) subsequent to each incubation. The distribution of the target protein in the cells was analyzed by confocal laser scanning microscopy (LSM 510; Carl Zeiss Microscopy GmbH, Jena, Germany). For the counterstaining of cell nuclei with B23 or fibrillarin, cells were incubated with nuclear fluorochrome Hoechst 33342 (10 mg/l) for 15 min at room temperature, followed by three washes in PBS.

### Western blotting assay

Cells were washed with cold PBS and transferred to a 1.7 ml centrifuge tube (Genetimes Biological Mall) where they were centrifuged at 200 × g for 5 min at 4°C. Lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid and 1% Triton X-100; pH, 7.4; Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) was added according to the proportion of 1 ml lysis buffer in 10^7^ cells. Following agitation for 15 min at 4°C, centrifugation at 12,000 × g was performed for 15 min at 4°C. The supernatant was collected as whole cell protein extract. The sample proteins of whole HEp-2 cell lysate (20 µg protein) were run on 12.5% sodium dodecyl sulfate-polyacrylamide gels, followed by transferal onto polyvinyl difluoride (PVDF) membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). GAPDH was used as a loading control. The PVDF membranes were initially blocked with 5% milk in TBS-T (NaCl, 80 g/l; KCl, 2 g/l; Tris, 30 g/l; Tween-20, 0.1%; pH 7.4; Sinopharm Chemical Reagent Co., Ltd.) for 1 h at room temperature and subsequently incubated with the primary antibodies against RhoA and GAPDH at 4°C overnight. Following the incubation of the membranes with the anti-IgG HRP-conjugated secondary antibody for 1 h at room temperature, ECL reagents were used to indicate the positive bands on the membrane, according to the manufacturer\'s protocol. The bands were detected using the Typhoon 9400 (GE Healthcare Life Sciences).

### Statistical analysis

A comparison of the amount of total RhoA protein following treatment with varying concentrations of actinomycin D was evaluated by one-way analysis of variance using SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### The subcellular redistribution of nucleolar RhoA following actinomycin D treatment in HEp-2 cells

Confocal laser scanning microscopy revealed the nuclear localization of RhoA with predominant accumulation in the cell nucleolus in HEp-2 cells with no drug treatment ([Fig. 1A](#f1-ol-0-0-4450){ref-type="fig"}), whereas treatment with actinomycin D altered the subcellular distribution of RhoA within the cell nucleus. Corresponding differential interference contrast pictures revealed large nucleoli in untreated HEp-2 cells ([Fig. 1B](#f1-ol-0-0-4450){ref-type="fig"}). Accompanied by a decrease in nucleolar staining, a bright nucleoplasmic speckle staining of RhoA was visualized in the cells ([Fig. 1C, E and G](#f1-ol-0-0-4450){ref-type="fig"}). However, the segregated nucleoli or nucleolus-like bodies were observed in the cells treated with actinomycin D ([Fig. 1D, F and 1H](#f1-ol-0-0-4450){ref-type="fig"}; arrows).

### Altered subcellular localization of nucleolar protein B23 in HEp-2 cells following actinomycin D treatment

Intracellular localization of two abundant nucleolar proteins fibrillarin and B23 was additionally examined by indirect immunofluorescence ([Fig. 2](#f2-ol-0-0-4450){ref-type="fig"}). Nucleolar protein B23 is well-known to relocalize following treatment with actinomycin D in numerous cell types, including HEp-2 cells ([@b21-ol-0-0-4450]--[@b28-ol-0-0-4450]). The staining for B23 was concentrated in the nucleoli of untreated HEp-2 cells ([Fig. 2A](#f2-ol-0-0-4450){ref-type="fig"}), but was redistributed diffusely throughout the nucleus following 4 h of treatment with 0.05 mg/l actinomycin D ([Fig. 2B](#f2-ol-0-0-4450){ref-type="fig"}). This redistribution of B23 may act as a marker for effective treatment by actinomycin D. Another abundant nucleolar protein, fibrillarin, demonstrated exclusively nucleolar localization in untreated cells ([Fig. 2E](#f2-ol-0-0-4450){ref-type="fig"}). Consistent with the previous finding, a redistribution of fibrillarin to the nucleoplasmic small entities was induced by actinomycin D ([Fig. 2F](#f2-ol-0-0-4450){ref-type="fig"}).

### RhoA protein content is unchanged following actinomycin D treatment

Following treatment with actinomycin D for 4 h, HEp-2 cells were washed with PBS and lysed under denaturing conditions. The protein amounts from whole-cell lysate were compared through immunoblotting analysis. Regardless of the various concentrations of actinomycin D, immunoblotting revealed a single band exclusively at 21 kDa for all untreated and actinomycin D-treated groups ([Fig. 3](#f3-ol-0-0-4450){ref-type="fig"}). Statistical analysis on the amount of total RhoA protein following various treatments with actinomycin D demonstrated no change in total cellular RhoA content (P\>0.05). Therefore, the actinomycin D treatment did not affect the net protein amount of RhoA, whilst it did affect the cellular distribution of the RhoA protein.

### Nuclear redistribution of RhoA is reversible

To investigate the persistence and reversibility of the actinomycin D-induced nuclear redistribution of RhoA, HEp-2 cells were initially treated with actinomycin D, followed by an additional cultivation in fresh culture medium without actinomycin D for at least 24 h. When HEp-2 cells were incubated with 0.05 mg/l actinomycin D for 4 h, a redistribution of RhoA was observed ([Fig. 4A](#f4-ol-0-0-4450){ref-type="fig"}). Removal of the drug from the culture medium allowed the reaccumulation of RhoA in the cell nucleoli 24 h later ([Fig. 4B](#f4-ol-0-0-4450){ref-type="fig"}). However, reaccumulation was not observed following initial treatment with an increased concentration of actinomycin D (1 mg/l for 1 h) ([Fig. 4C](#f4-ol-0-0-4450){ref-type="fig"}), even when the incubation time without actinomycin D was extended to 27 h ([Fig. 4D](#f4-ol-0-0-4450){ref-type="fig"}).

Discussion
==========

Over the past few decades, the understanding of nucleolar function has changed markedly with the concept of the plurifunctional nucleolus ([@b9-ol-0-0-4450]). Proteomic studies have suggested that the cell nucleolus may be involved in a wide range of cellular processes independent of ribosome biogenesis ([@b29-ol-0-0-4450]). Extensive evidence indicates that the nucleolus affects the response to cellular stress, and regulates the cell cycle and cell growth ([@b29-ol-0-0-4450]). Perturbations to the nucleolus have been reported in a wide range of cellular diseases, from autoimmunity to cancer ([@b30-ol-0-0-4450]).

An important aspect regarding nucleolus structure and function are the morphological variations that exist between normal somatic and neoplastic or malignant cells ([@b31-ol-0-0-4450]). For over a century, an increase in the size and number of cell nucleoli has been utilized as a marker of aggressive tumors ([@b31-ol-0-0-4450],[@b32-ol-0-0-4450]). Contemporary studies have inferred that nucleoli may have a broad role in malignant transformation. Specifically, the extra-ribosomal functions of the nucleolus position the organelle as a central integrator of cellular proliferation and stress signaling and are emerging as important mechanisms for modulating how oncogenes and tumor suppressors operate in normal and malignant cells ([@b33-ol-0-0-4450]).

Research has demonstrated that RhoA serves a key role in governing extra- and intracellular signaling transduction, in addition to being involved in numerous biological processes, including tumorigenesis ([@b34-ol-0-0-4450]). RhoA, as the most extensively investigated member of the Rho protein family, acts as a molecular switch in cells, regulating signal transduction from cell surface receptors to intracellular target molecules, and is involved in a number of biological processes, including cell morphology, motility and tumor progression ([@b34-ol-0-0-4450]). Without destroying the cells, the present study demonstrated a redistribution of nucleolar RhoA between the nucleoli and the nucleoplasm with a speckled staining pattern following the treatment of HEp-2 cells with actinomycin D. Furthermore, immunoblotting revealed a single band exclusively at 21 kDa, indicating that an actinomycin D-induced decrease in nucleolar RhoA was not accompanied by any alteration in RhoA protein content, biochemical modification or cleavage of RhoA. These results are concordant with previous findings regarding the nucelolar protein fibrillarin following treatment with actinomycin D. The present results demonstrating that the nucleolar protein B23 translocated to the nucleoplasm, along with redistribution of nucleolar fibrillarin to the nucleoplasm following treatment with actinomycin D, are also consistent with previous observations made in various types of cells ([@b24-ol-0-0-4450],[@b28-ol-0-0-4450]). As actinomycin D may displace RNA polymerases by binding DNA and subsequently inhibiting RNA synthesis ([@b35-ol-0-0-4450]), the present results may reflect the redistribution of RhoA between the nucleoli and nucleoplasm when RNA synthesis is inhibited.

At low concentrations (0.04--0.05 mg/l), actinomycin D selectively inhibits transcription that is mediated by RNA polymerase I in the nucleolus, but not transcription mediated by RNA polymerase II and III ([@b36-ol-0-0-4450]). The reaccumulation of RhoA occurred between the nucleoplasm and the nucleoli following removal of the lower concentration (0.05 mg/l) of actinomycin D, which extended the aforementioned results due to the observation that the effect on the subcellular redistribution of RhoA induced by low concentrations of actinomycin D was reversible. However, due to the action of actinomycin D on RNA polymerases II and III at increased concentrations, even subsequent to an extended period of drug removal, the displacement of RhoA was irreversible upon treatment of cells with increased concentrations of actinomycin D, which led to severe inhibition of RNA synthesis. The DFC and the edge of the FC are the nucleolar regions where transcription takes place ([@b7-ol-0-0-4450]). Although the exact location of RhoA in respect to the nucleolar component remains to be elucidated, considering the similar nucleolar localization of RhoA and transcription sites, the observation of actinomycin D-induced redistribution of nucleolar RhoA to the nucleoplasm revealed direct evidence that the residency of RhoA in the nucleolus was dependent on active transcription.

In line with the present results, the βII-subunit of tubulin, a major subunit of microtubules that was previously considered to exist solely in the cytoplasm of cells, has also been identified to localize to the nuclei, with a strong aggregation in the nucleoli of numerous types of carcinoma cells ([@b37-ol-0-0-4450],[@b38-ol-0-0-4450]). Following treatment with the drug taxol, which inhibits mitosis targeted at the microtubules of dividing cells, βII-tubulin underwent a rearrangement in the nuclei and demonstrated the formation of micronuclei ([@b37-ol-0-0-4450]). Increasing evidence emerged that these cellular proteins may be dynamic, crossing through the cytoplasm, nucleoplasm and nucleolus to perform their roles, and a number of these proteins may remain to be elucidated ([@b16-ol-0-0-4450],[@b18-ol-0-0-4450],[@b38-ol-0-0-4450]).

In the current era of translational medicine, the newly recognized roles of the nucleolus raise the possibility that cancer drug discovery and emerging chemotherapy may identify a foundation in the nucleolus or nucleolar proteins to a greater degree than had been anticipated ([@b35-ol-0-0-4450]). Knowledge of the location, function and duration of the residency of proteins in the nucleolus is vital in identifying additional drug targets in the nucleolus.

In conclusion, the results of the present study provided *in situ* evidence that actinomycin D induced a redistribution of nucleolar RhoA to the nucleoplasm in human carcinoma HEp-2 cells. In addition, the results indicated that the residency of RhoA in the cell nucleolus is associated with active RNA synthesis. To the best of our knowledge, these results provide the first information regarding nucleolar RhoA in association with nucleolar function. Additional investigations on the nuclear or nucleolar functioning of RhoA are underway and may provide novel considerations for cancer therapy.
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![Alteration of the intracellular localization of RhoA induced by actinomycin D in HEp-2 cells. (A) Indirect immunofluorescence revealed prominent nucleolar RhoA in untreated cells. (B) Corresponding cells were revealed in differential interference contrast pictures. Redistribution of nucleolar RhoA to nucleoplasmic speckles was observed in the cells treated with actinomycin D at the concentrations of (C) 0.05 mg/l, (D) differential interference contrast; (E) 0.10 mg/l, (F) differential interference contrast; and (G) 1.00 mg/l for 4 h, (H) differential interference contrast. Arrows represent the segregated nucleoli or nucleolus-like bodies. Scale bar, 10 µm. RhoA, ras homolog family member A.](ol-11-06-3605-g00){#f1-ol-0-0-4450}

![Actinomycin D altered the subcellular location of nucleolar proteins B23 and fibrillarin in HEp-2 cells. Cells showed nucleolar localization of B23 (A) without treatment and (B) with 0.05 mg/l actinomycin D for 4 h. B23 translocated from the nucleoli to the nucleoplasm in a diffuse staining pattern. (C and D) Corresponding cell nuclei were shown by nuclear staining with Hoechst 33342. Cells demonstrated nucleolar localization of fibrillarin (E) without treatment and (F) with 0.05 mg/l actinomycin D for 4 h. Fibrillarin redistributed to small nucleoplasmic entities. (G and H) Corresponding cell nuclei were shown by nuclear staining with Hoechst 33342. Scale bar, 5 µm. B23, nucleolar phosphoprotein B23.](ol-11-06-3605-g01){#f2-ol-0-0-4450}

![Immunoblotting of RhoA protein amount in whole HEp-2 cell lysate. Total RhoA protein was detected as a single band at 21 kDa in untreated cells and cells treated with actinomycin D for 4 h at the concentration of 0.05 mg/l, 0.1 mg/l or 1 mg/l. Glyceraldehyde-3-phosphate dehydrogense was used as a loading control. RhoA, ras homolog family member A.](ol-11-06-3605-g02){#f3-ol-0-0-4450}

![Localization of ras homolog family member A in HEp-2 cells following the removal of actinomycin D. (A) Cells treated with actinomycin D at a concentration of 0.05 mg/l for 4 h. (B) Cells treated with actinomycin D at a concentration of 0.05 mg/l for 4 h, washed and incubated for 24 h in drug-free culture medium. (C) Cells treated with actinomycin D at a concentration of 1 mg/l for 1 h. (D) Cells treated with actinomycin D at a concentration of 1 mg/l for 1 h, washed and incubated for 27 h in drug-free culture medium. Scale bar, 10 µm.](ol-11-06-3605-g03){#f4-ol-0-0-4450}
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